Abrocitinib as a Novel Treatment for Multiple Skin Disorders: 3 Case Reports and a Scoping Review
Authors:
Open Access
- 1 January 2024
- journal article
- review article
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 17, 35-40
Abstract
Janus kinase (JAK) inhibitors are increasingly being used in dermatology due to their broad potential in managing both local and systemic inflammation. More recently, abrocitinib, an oral JAK 1 inhibitor, has shown promising clinical efficacy in the treatment of various skin disorders beyond moderate to severe atopic dermatitis (AD). We firstly presented three cases, each with diagnosis of pyoderma gangrenosum (PG), livedoid vasculopathy (LV), or hidradenitis suppurativa (HS), and conducted a comprehensive scoping review of the available literature on the use of abrocitinib in the treatment of diverse skin disorders. We summarized a total of 16 skin disorders, including our cases. The results indicated that abrocitinib, whether used as monotherapy or in combination with other treatments, was effective and well-tolerated in these disorders. These findings expanded the range of diseases for which abrocitinib may serve as an alternative therapeutic choice.Keywords
This publication has 15 references indexed in Scilit:
- Failure of Dupilimab with Severe Prurigo Nodularis That Responded Well to AbrocitinibDermatitis®, 2023
- Treatment of Netherton Syndrome With AbrocitinibJAMA Dermatology, 2023
- Treatment of primary cutaneous lichenoid amyloidosis with abrocitinib: A pilot study in two casesInternational Journal of Dermatology, 2023
- Abrocitinib as a novel treatment for lichen sclerosusBritish Journal of Dermatology, 2023
- The Janus kinase 1 inhibitor abrocitinib for the treatment of oral lichen planusJournal of the European Academy of Dermatology and Venereology, 2023
- Improvement of Hailey–Hailey disease with abrocitinibClinical and Experimental Dermatology, 2023
- Occupational airborne allergic contact dermatitis to invasive Compositae species treated with abrocitinib: A case reportContact Dermatitis, 2022
- Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND)Journal of the American Academy of Dermatology, 2022
- Successful treatment of chronic severe alopecia areata with abrocitinibAustralasian Journal of Dermatology, 2022
- A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinibJAAD Case Reports, 2022